100% Quality Guarantee
PhD-Level Technical Support
Key Features

Human TNF-alpha/TNFA Recombinant Protein (RPES1664)

SKU RPES1664
Product Type Recombinant Protein
Species Human
Application Area Cytokines & Chemokines
€285 - €645

Request a formal quotation

A PDF quote with its own quote number, ready for your purchasing office to raise a PO against. Back within 4 working hours, from a PhD scientist — not an autoresponder.

  • PO-ready PDFQuote number, VAT, Incoterms
  • Volume pricing appliedDiscounts from 2 kits up
  • Valid 30 daysPrices held while you get sign-off
Anything we should know? optional

No account needed. We use your details only to prepare and send this quote. If it's urgent, say so in the box and we'll come back the same working day.

Global Shipping: 80+ Countries
White Glove Service: Available upon request
Batch Consistency: Contact Sales
Distributors: 60+ Countries

Description

system_update_altDatasheetsystem_update_altMSDS

Human TNF-alpha/TNFA Recombinant Protein

Tumor Necrosis Factor-? (TNF-?) is secreted by macrophages; monocytes; neutrophils; T-cells; and NK-cells following stimulation by bacterial LPS. Cells expressing CD4 secrete TNF-? while cells that express CD8 secrete little or no TNF-?. Synthesis of TNF-? can be induced by many different stimuli including interferons; IL2; and GM-CSF. The clinical use of the potent anti-tumor activity of TNF-? has been limited by the proinflammatory side effects such as fever; dose-limiting hypotension; hepatotoxicity; intravascular thrombosis; and hemorrhage. Designing clinically applicable TNF-? mutants with low systemic toxicity has been of intense pharmacological interest. Human TNF-? that binds to murine TNF-R55 but not murine TNF-R7; exhibits retained anti-tumor activity and reduced systemic toxicity in mice compared with murine TNF-?; which binds to both murine TNF receptors. Based on these results; many TNF-? mutants that selectively bind to TNF-R55 have been designed. These mutants displayed cytotoxic activities on tumor cell lines in vitro and have exhibited lower systemic toxicity in vivo. Recombinant Human TNF-? High Active Mutant differs from the wild-type by amino acid subsitution of amino acids 1-7 with Arg8; Lys9; Arg10 and Phe157. This mutant form has been shown to have increased activity with less inflammatory side effects in vivo.

View AllClose

0 Reviews

0
Based on 0 reviews

No reviews yet. Be the first to share your experience!

View AllClose